Recently, in a larger study of patients with additional neurological presentations, SOX1 antibodies were found in 2/247 (0.8%) patients with multiple sclerosis, 2/185 (1.1%) with neuropathy of unknown cause and 11/837 (1.3%) with suspected PNDs, most of whom had no underlying tumour, and none with SCLC (Berger et al., 2016). This evidence concerns the gene SOX1 and neoplasm.